how to use hexarelin: Frequently asked questions

Missing 2–3 doses in a 28-day cycle reduces cumulative receptor occupancy but doesn't fully reset desensitisation timelines. Resume dosing immediately and extend the cycle by the number of missed days. If you missed 3 doses, run the 'on' phase for 31 days instead of 28 before initiating the washout. Missing more than 5 consecutive doses eliminates the sustained receptor binding that creates the protective state. At that point, restart the 4-week cycle from day one rather than trying to salvage partial coverage.

Reduce your dose to 100–150 mcg and shift timing to once daily instead of multiple daily pulses. The cardioprotective effect requires sustained CD36 receptor occupancy, which is achieved at lower single doses, while GH-focused protocols use higher doses (200–300 mcg) multiple times daily to create pulsatile pituitary stimulation. You can't optimise both outcomes simultaneously with the same dosing structure. The mechanisms operate on different receptor systems. If cardioprotection is the priority, dose at 100 mcg once daily pre-stress. If GH release is the priority, use a different GHRP (ipamorelin, GHRP-2) that doesn't carry the same receptor desensitisation risk at CD36 sites.

Administer the missed dose as soon as you remember, provided you are still in a fasted state (at least 2 hours post-meal). If you are within 1 hour of your next scheduled meal, skip the missed dose entirely and resume your normal schedule the following day. Do not double-dose to compensate. Administering 400–600 mcg at once does not produce proportionally higher GH output and significantly increases desensitisation risk. Missing 1–2 doses per week has minimal impact on overall study outcomes; missing doses during the first 10 days of a new cycle matters more than missing doses in weeks 3–4 when receptor density has already adjusted.

These symptoms typically indicate transient hypoglycemia triggered by the GH-insulin interaction. Hexarelin-stimulated GH release transiently increases insulin sensitivity, which can drop blood glucose rapidly in a fasted state. If symptoms occur, consume 10–15 grams of fast-acting carbohydrates (glucose tablets, fruit juice) and monitor resolution within 10–15 minutes. If symptoms persist beyond 30 minutes or worsen, discontinue hexarelin and consult the supervising investigator. Hypoglycemia in research subjects requires protocol review.

This is expected. Receptor desensitisation begins around week 6 with continuous daily dosing. If you are administering Hexarelin at 200–300 mcg daily without breaks, GH output will decline progressively regardless of dose accuracy or timing. The solution is not to increase the dose (which accelerates desensitisation further) but to implement a structured pause. Discontinue Hexarelin for 10–14 days, during which GHS-R1a receptor density on pituitary somatotrophs returns toward baseline. When you resume dosing after this washout period, initial GH response should recover to 80–90% of original levels. For research requiring extended Hexarelin use beyond 8 weeks, transition to a pulsed protocol (5 days dosing, 2 days off) from the outset rather than waiting for desensitisation to manifest.

Verify injection timing precision first. Even 10-minute deviations from the 30-minute pre-treatment window reduce efficacy significantly. Second, confirm the ischemia duration was sufficient to induce measurable injury in control animals: if control infarct size is <30% of area-at-risk, the baseline injury may be too mild to demonstrate protection. Third, check peptide storage conditions throughout the study. Temperature excursions during shipping or storage are the most common cause of unexplained potency loss. Request a Certificate of Analysis from Real Peptides to verify batch purity matched specifications.

Don't. The GH response curve plateaus and declines after week three due to receptor downregulation. Extending the cycle wastes peptide without proportional benefit. If your research protocol requires sustained GH elevation beyond four weeks, rotate to a different growth hormone secretagogue during the hexarelin off-phase. Alternating between hexarelin and other GHSPs like CJC-1295 or ipamorelin during separate cycle blocks preserves receptor sensitivity across both compounds and maintains consistent GH output over longer study durations.

Cardioprotection is a physiological state, not a subjective sensation. Most individuals feel nothing different day-to-day. Measure HRV with a wearable device or clinical-grade monitor; track resting heart rate and post-exertion recovery time; request hs-CRP bloodwork if accessible. If those markers show no improvement after 3–4 weeks at 100–150 mcg daily, either the dose is insufficient for your body weight (consider increasing to 150–200 mcg), or your baseline cardiovascular health is already optimised and hexarelin is providing marginal benefit. The compound's effect is most pronounced in individuals with elevated oxidative stress, metabolic syndrome, or cardiovascular risk factors. Healthy baseline populations see smaller absolute changes.

Discard the vial and reconstitute fresh peptide. Hexarelin undergoes irreversible protein denaturation above 8°C. A single 12-hour ambient temperature excursion reduces bioactive peptide concentration by 30–50% even when the solution appears clear and particulate-free. There is no reliable way to assess potency loss visually or through standard lab equipment outside of mass spectrometry. The financial cost of discarding one compromised vial is far lower than running an entire study with degraded peptide that produces non-reproducible results.

Water retention (peripheral oedema, bloating) occurs in approximately 10–15% of research models and results from GH-induced sodium retention in renal tubules. It's dose-dependent: higher doses (300mcg+ per injection) increase aldosterone co-secretion. Reduce dose to 100–150mcg per injection and increase hydration to 3+ litres daily. Paradoxically, drinking more water reduces retention by diluting plasma aldosterone. If retention persists, discontinue for 48 hours to allow renal clearance, then resume at lower dose. Persistent oedema beyond 72 hours post-cessation is uncommon and warrants discontinuation.

GH pulse amplitude drops by 40–60% when administered within 2 hours of eating. Elevated blood glucose triggers insulin secretion, which activates somatostatin. A hypothalamic hormone that directly inhibits GH release from pituitary somatotrophs. The Hexarelin still binds ghrelin receptors correctly, but downstream signalling is blunted. If you've already injected post-meal, the dose isn't wasted entirely. You'll see a smaller GH elevation. But it's suboptimal. For maximum lipolytic effect, administer only during fasted windows: immediately upon waking or at least 3 hours after lunch.

Discard the vial immediately. Do not attempt to filter or use it. Cloudiness indicates bacterial contamination, protein aggregation, or incomplete dissolution, all of which render the peptide ineffective and potentially unsafe. Hexarelin in proper solution is clear and colourless; any deviation from this appearance means the molecular structure has been compromised. Recheck your reconstitution technique: bacteriostatic water should be injected slowly down the vial wall (never directly onto the powder), and the vial should be swirled gently rather than shaken. If cloudiness recurs with a fresh vial and new bacteriostatic water, the lyophilised powder itself may have been exposed to temperature excursions during shipping or storage before you received it.

Rotate injection sites with every administration across at least four distinct anatomical locations: lower abdomen left and right of the navel, anterior thigh (vastus lateralis), and dorsogluteal region. Lipohypertrophy. Localised fat accumulation at repeatedly used injection sites. Develops when the same 1-inch area is injected more than twice per week. The condition is reversible but takes 8–12 weeks of site avoidance to resolve, and it reduces peptide absorption by 20–40% while present. If redness, swelling, or warmth develops at an injection site and persists beyond 24 hours, this indicates localised inflammation or infection rather than normal post-injection response. Cease injections at that site, apply a warm compress, and monitor for systemic symptoms (fever, spreading redness). Research-grade peptides from verified sources like Real Peptides undergo rigorous purity testing to minimise reaction risk, but individual sensitivity to bacteriostatic water or benzyl alcohol preservatives can still occur.

Missing a single dose has negligible impact on cumulative GH exposure over a 4–6 week cycle. Resume your normal schedule at the next planned injection. Do not double-dose to compensate. Doubling doses increases cortisol co-release without proportional GH benefit and accelerates receptor desensitisation. If you miss an entire day (both morning and evening doses), simply continue the cycle as planned. Missing 3+ consecutive days may justify extending the cycle by those days to maintain total peptide exposure, but this is optional.

Administer the missed dose as soon as you remember, provided you are still in a fasted state or at least two hours post-meal. If you realize the missed dose during or immediately after eating, skip it and resume the normal schedule at the next planned injection time. Do not double-dose to compensate. Administering 400 mcg at once does not produce proportionally higher GH output and increases the risk of acute side effects like transient hypoglycemia or cortisol elevation.

Administer at the earliest possible moment, but expect significantly reduced cardioprotective effect. Post-ischemic Hexarelin administration (even 10 minutes after LAD occlusion) reduces infarct size reduction from 43% to approximately 15–18% compared to saline controls. The peptide's mechanism requires pre-activation of PI3K/Akt and ERK1/2 signaling pathways. These cascades take 15–20 minutes to reach full activity after receptor binding, meaning post-ischemic dosing arrives after the critical injury window has passed.

Do not use it. Cloudiness or visible particulate matter indicates peptide aggregation, contamination, or improper reconstitution technique. Hexarelin solution should be clear and colorless after proper reconstitution. Aggregated peptide has reduced bioactivity and may trigger immune responses. Discard the vial and reconstitute a fresh aliquot using slower water injection technique and gentler swirling motion. If cloudiness recurs with fresh peptide, the lyophilized powder may have been exposed to temperature excursions during shipping or storage before reconstitution.